# Neuralink — Healthcare Investment Intelligence

> medical_device · Series C+. MedFuel Intel profile as of 2026-06-12.

Neuralink is developing implantable brain-computer interfaces (BCIs) with high-channel electrodes for patients with paralysis from spinal cord injuries or ALS, having received FDA approval for human trials in May 2023 and implanted its first patient in January 2024.[1][2][5] The company, founded by Elon Musk in 2016, has raised significant funding through multiple venture rounds and is advancing clinical trials as of summer 2025.[1][3]

## Key facts (as of 2026-06-12)
- Sector: medical_device
- Stage: Series C+
- Website: https://neuralink.com

## MedFuel assessment
- Intelligence score: 0/100
- Analyses: 0
- Sentiment trend: stable

---
Source: MedFuel Intel — https://medfuelintel.com/company/neuralink-25. Figures reflect MedFuel's analysis; verify against primary sources (SEC, FDA, ClinicalTrials.gov) before any investment decision.